{"id":"von-willebrand-factor","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4298126","moleculeType":"Unknown"},"_dailymed":{"setId":"53b6d198-6175-4a26-8606-dc0d2a0f12d6","title":"VONVENDI (VON WILLEBRAND FACTOR (RECOMBINANT)) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"vWF binds to exposed collagen and other subendothelial components at sites of vascular injury, enabling platelet adhesion and aggregation. It also stabilizes and carries factor VIII in the bloodstream, preventing its degradation and ensuring adequate coagulation capacity. Replacement therapy restores both hemostatic platelet function and factor VIII levels in patients with deficiency.","oneSentence":"Von Willebrand factor (vWF) is a blood glycoprotein that mediates platelet adhesion to damaged blood vessel walls and serves as a carrier protein for clotting factor VIII.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:57:22.459Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Von Willebrand disease (Types 1, 2, and 3)"},{"name":"Hemophilia A (as factor VIII carrier)"}]},"trialDetails":[{"nctId":"NCT06998524","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-06-27","conditions":"Von Willebrand Disease, Type 3","enrollment":75},{"nctId":"NCT06883240","phase":"","title":"An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-29","conditions":"Von Willebrand Disease, Type 3","enrollment":40},{"nctId":"NCT06433778","phase":"","title":"A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-12-16","conditions":"Von Willebrand Disease (VWD)","enrollment":34},{"nctId":"NCT07439939","phase":"","title":"Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-02","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":45},{"nctId":"NCT07404644","phase":"","title":"An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-02-19","conditions":"Von Willebrand Disease (vWD)","enrollment":13},{"nctId":"NCT04953884","phase":"PHASE3","title":"Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age","status":"COMPLETED","sponsor":"Octapharma","startDate":"2021-09-22","conditions":"Von Willebrand Disease","enrollment":12},{"nctId":"NCT07418099","phase":"","title":"External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis","status":"RECRUITING","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2026-01-13","conditions":"Coagulation Disorder, Blood, Prolonged APTT","enrollment":1500},{"nctId":"NCT07422974","phase":"","title":"Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer","status":"RECRUITING","sponsor":"Osijek University Hospital","startDate":"2026-01-09","conditions":"Colorectal Carcinoma (CRC), Complications, Neoadjuvant Therapy","enrollment":68},{"nctId":"NCT06579144","phase":"PHASE1","title":"Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-02-24","conditions":"Hemophilia A","enrollment":24},{"nctId":"NCT07410130","phase":"","title":"Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03","conditions":"Von Willebrand Disease (VWD), Inherited Bleeding Disorders in Children, Pediatric Hemostatic Disorders","enrollment":25},{"nctId":"NCT07400848","phase":"","title":"Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome","status":"RECRUITING","sponsor":"University of Bern","startDate":"2026-02-15","conditions":"Post-Acute COVID-19 Vaccination Syndrome, Postviral Fatigue","enrollment":200},{"nctId":"NCT06118372","phase":"PHASE1","title":"Recombinant vWF Concentrate and ECMO","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-10-03","conditions":"Bleeding Disorder","enrollment":12},{"nctId":"NCT06716814","phase":"PHASE3","title":"Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-03-06","conditions":"Severe Haemophilia A","enrollment":104},{"nctId":"NCT07363187","phase":"","title":"Nailfold Capillaroscopy and Endothelial Biomarkers in Healthcare Workers Exposed to Chronic Low-Dose Ionizing Radiation","status":"NOT_YET_RECRUITING","sponsor":"Istanbul Training and Research Hospital","startDate":"2026-02-01","conditions":"Microvascular Dysfunction, Endothelial Dysfunction, Occupational Radiation Exposure","enrollment":90},{"nctId":"NCT07358013","phase":"","title":"Endothelial Colony-Forming Cells in Patients With VWD, AVWS and Healthy Subjects","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2023-11-11","conditions":"Von Willebrand Disease (VWD), Acquired Von Willebrand Disease","enrollment":48},{"nctId":"NCT04268940","phase":"","title":"Thrombo-Elastography Guided Management of ECMO","status":"COMPLETED","sponsor":"Damian Ratano","startDate":"2020-06-03","conditions":"Extracorporeal Circulation of Blood; Thrombocytopenia","enrollment":61},{"nctId":"NCT06610201","phase":"","title":"A Study of Bleeding and Treatment in Participants With Von Willebrand Disease","status":"RECRUITING","sponsor":"Hemab ApS","startDate":"2024-08-30","conditions":"Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2","enrollment":200},{"nctId":"NCT07129343","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-10-13","conditions":"Von Willebrand Disease (VWD)","enrollment":20},{"nctId":"NCT02972008","phase":"","title":"Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2017-03-09","conditions":"Cognitive Decline, Stroke","enrollment":542},{"nctId":"NCT04146376","phase":"","title":"Von Willebrand Factor in Pregnancy (VIP) Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2019-10-12","conditions":"Von Willebrand Diseases","enrollment":110},{"nctId":"NCT06754852","phase":"PHASE1, PHASE2","title":"A Study Assessing HMB-002 in Participants With Von Willebrand Disease","status":"RECRUITING","sponsor":"Hemab ApS","startDate":"2025-02-06","conditions":"Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2","enrollment":108},{"nctId":"NCT07273721","phase":"PHASE2","title":"Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2025-08-14","conditions":"Von Willebrand Disease (VWD), Type 2","enrollment":6},{"nctId":"NCT07265843","phase":"PHASE4","title":"Fibrinogen in Liver Transplant","status":"NOT_YET_RECRUITING","sponsor":"Trauma Hemostatis and Oxygenation Research (THOR) Network","startDate":"2026-01-01","conditions":"Liver Transplant Surgery","enrollment":60},{"nctId":"NCT03070912","phase":"","title":"Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2018-01-19","conditions":"Von Willebrand Diseases","enrollment":257},{"nctId":"NCT03695978","phase":"","title":"Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients","status":"RECRUITING","sponsor":"Octapharma","startDate":"2018-02-13","conditions":"Haemophilia A","enrollment":200},{"nctId":"NCT04344860","phase":"PHASE3","title":"Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial","status":"COMPLETED","sponsor":"Nicoletta C Machin","startDate":"2021-06-04","conditions":"Von Willebrand Diseases, Postpartum Hemorrhage","enrollment":20},{"nctId":"NCT05582993","phase":"PHASE3","title":"A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-06","conditions":"Von Willebrand Disease (VWD)","enrollment":24},{"nctId":"NCT05817812","phase":"PHASE3","title":"A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2023-07-31","conditions":"Hemophilia A, Severe","enrollment":93},{"nctId":"NCT07083583","phase":"","title":"Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders","status":"RECRUITING","sponsor":"Nicoletta C Machin","startDate":"2025-08-08","conditions":"Bleeding Disorders, Iron, Platelet","enrollment":40},{"nctId":"NCT04161495","phase":"PHASE3","title":"A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2019-11-19","conditions":"Factor VIII Deficiency","enrollment":159},{"nctId":"NCT04759131","phase":"PHASE3","title":"Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2021-02-19","conditions":"Hemophilia A","enrollment":74},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT06173024","phase":"","title":"Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)","status":"AVAILABLE","sponsor":"Takeda","startDate":"","conditions":"Von Willebrand Disease (VWD)","enrollment":""},{"nctId":"NCT03879135","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2019-04-01","conditions":"Von Willebrand Disease (VWD)","enrollment":38},{"nctId":"NCT04951999","phase":"NA","title":"AssocIation of PULSatility and Occurrence of Complications Related to Mechanically Assisted Circulatory Support","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-02","conditions":"End-stage Heart Failure","enrollment":27},{"nctId":"NCT06273865","phase":"","title":"Version Testing of EnzySystem Version A for Hemophilia A","status":"SUSPENDED","sponsor":"Radboud University Medical Center","startDate":"2024-05-29","conditions":"Hemophilia A","enrollment":40},{"nctId":"NCT06001645","phase":"","title":"Laboratory Biomarkers and Pulmonary Interstitial Emphysema in ARDS (PIE-ARDS)","status":"RECRUITING","sponsor":"Università Vita-Salute San Raffaele","startDate":"2023-11-27","conditions":"Acute Respiratory Distress Syndrome, Barotrauma","enrollment":110},{"nctId":"NCT06764927","phase":"PHASE4","title":"Fibrinogen in Liver Transplant Subjects","status":"NOT_YET_RECRUITING","sponsor":"Ezeldeen Abuelkasem","startDate":"2025-10-31","conditions":"Liver Transplant Surgery","enrollment":30},{"nctId":"NCT04644575","phase":"PHASE3","title":"Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bioverativ, a Sanofi company","startDate":"2021-02-23","conditions":"Hemophilia A","enrollment":261},{"nctId":"NCT03598907","phase":"","title":"Point-of-care Management of Coagulopathy in Lung Transplantation","status":"TERMINATED","sponsor":"University Hospital, Motol","startDate":"2018-01-01","conditions":"Lung Transplantation","enrollment":100},{"nctId":"NCT06585930","phase":"","title":"Relation Between the Value of Platelet Clot Stiffness (PCS) Obtained by Sonorheometric Method of Delocalized Hemostasis (QUANTRA®), and the Presence of a Disorder of Primary Hemostasis, in Cardiac Surgery Patients. PLAQUA-Study","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2024-08-30","conditions":"Primary Haemostasis Disorder in Cardiac Surgery Patients","enrollment":100},{"nctId":"NCT02932618","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)","status":"RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2017-11-06","conditions":"Von Willebrand Disease","enrollment":31},{"nctId":"NCT04887324","phase":"","title":"Real-life Data of Constitutional Von Willebrand Disease in Western France","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2023-07-07","conditions":"Von Willebrand Diseases","enrollment":922},{"nctId":"NCT02869074","phase":"","title":"Molecular and Clinical Profile of Von Willebrand Disease in Spain","status":"COMPLETED","sponsor":"Spanish Society of Thrombosis and Haemostasis","startDate":"2017-10-03","conditions":"Von Willebrand Disease","enrollment":790},{"nctId":"NCT03853486","phase":"","title":"ATHN 9: Severe VWD Natural History Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2019-06-18","conditions":"Von Willebrand Diseases","enrollment":108},{"nctId":"NCT02460458","phase":"","title":"Type 3 Von Willebrand International Registries Inhibitor Prospective Study","status":"COMPLETED","sponsor":"Fondazione Angelo Bianchi Bonomi","startDate":"2012-11-05","conditions":"Type 3 Von Willebrand's Disease","enrollment":265},{"nctId":"NCT06205095","phase":"PHASE3","title":"A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD","status":"RECRUITING","sponsor":"Unity Health Toronto","startDate":"2024-10-21","conditions":"Von Willebrand Diseases","enrollment":20},{"nctId":"NCT04555785","phase":"PHASE4","title":"Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-04-01","conditions":"Bleeding","enrollment":120},{"nctId":"NCT05010707","phase":"PHASE2","title":"Transgender Estradiol Affirming Therapy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-08-02","conditions":"Transgenderism","enrollment":39},{"nctId":"NCT06694090","phase":"","title":"Von Willebrand Factor Levels in Patients With Liver Cirrhosis and Portal Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-11-15","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":67},{"nctId":"NCT06304714","phase":"","title":"Effects of Bothrops Spp. Snake Envenomation on Willebrand Factor Activity in Martinique and French Guiana","status":"RECRUITING","sponsor":"University Hospital Center of Martinique","startDate":"2024-08-02","conditions":"Snake Envenomation, Thrombi, Coagulopathy","enrollment":30},{"nctId":"NCT06585995","phase":"NA","title":"Effectiveness and Safety of Two Vitamin D3 Supplementation Regimens in Adults with Early-stage COVID-19","status":"COMPLETED","sponsor":"Escuela Militar de Graduados de Sanidad, SEDENA","startDate":"2022-04-29","conditions":"COVID-19","enrollment":216},{"nctId":"NCT03344003","phase":"","title":"Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq","status":"TERMINATED","sponsor":"Octapharma","startDate":"2018-06-28","conditions":"Hemophilia A","enrollment":14},{"nctId":"NCT02472665","phase":"PHASE4","title":"Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease","status":"RECRUITING","sponsor":"Grifols Therapeutics LLC","startDate":"2013-12","conditions":"Von Willebrand Disease","enrollment":8},{"nctId":"NCT02606045","phase":"PHASE3","title":"Minimize Menorrhagia in Women With Von Willebrand Disease","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2019-02-07","conditions":"Von Willebrand Diseases","enrollment":39},{"nctId":"NCT05079009","phase":"NA","title":"Effects of Blood Pulsatility on Von Willebrand Factor During ECCO2R","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-01-28","conditions":"Extracorporeal CO2 Removal, Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease Exacerbation","enrollment":6},{"nctId":"NCT04657887","phase":"","title":"Registry of Patients With Von WilLEbrand Disease Treated With Voncento®","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2015-11-23","conditions":"Von Willebrand Disease","enrollment":135},{"nctId":"NCT06357572","phase":"","title":"Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem","status":"COMPLETED","sponsor":"Enzyre B.V.","startDate":"2024-03-26","conditions":"Hemophilia A With Inhibitor, Hemophilia A","enrollment":6},{"nctId":"NCT04810702","phase":"","title":"Impact of Von Willebrand Factor and Its Multimers on Angiogenesis","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-02-07","conditions":"Von Willebrand Diseases","enrollment":90},{"nctId":"NCT04053699","phase":"","title":"Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment","status":"COMPLETED","sponsor":"Octapharma","startDate":"2019-06-25","conditions":"Von Willebrand Diseases","enrollment":56},{"nctId":"NCT04052698","phase":"PHASE3","title":"Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD","status":"COMPLETED","sponsor":"Octapharma","startDate":"2020-06-18","conditions":"Von Willebrand Diseases","enrollment":43},{"nctId":"NCT01257269","phase":"","title":"Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2006-10","conditions":"Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura","enrollment":450},{"nctId":"NCT06066814","phase":"","title":"To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-10-07","conditions":"Acute on Chronic Liver Failure","enrollment":50},{"nctId":"NCT05265078","phase":"","title":"A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-06-08","conditions":"Von Willebrand Disease (VWD)","enrollment":102},{"nctId":"NCT00555555","phase":"PHASE4","title":"Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grifols Biologicals, LLC","startDate":"2007-09","conditions":"Von Willebrand Disease","enrollment":15},{"nctId":"NCT01151423","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2011-01","conditions":"Acquired Thrombotic Thrombocytopenic Purpura","enrollment":75},{"nctId":"NCT03728049","phase":"NA","title":"Von Willebrand Factor Point-of-care Testing to Improve Minimally Invasive TAVI Outcomes","status":"UNKNOWN","sponsor":"University Hospital, Lille","startDate":"2019-12-18","conditions":"Aortic Valve Stenosis, Aortic Valve Insufficiency","enrollment":944},{"nctId":"NCT05628558","phase":"","title":"Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A","status":"UNKNOWN","sponsor":"Groupe Maladies hémorragiques de Bretagne","startDate":"2020-07-01","conditions":"Hemophilia A, Mild, Desmopressin, Factor VIII","enrollment":800},{"nctId":"NCT05015244","phase":"NA","title":"Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2019-06-01","conditions":"Von Willebrand Disease, Type 2B","enrollment":5},{"nctId":"NCT02466789","phase":"","title":"Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)","status":"COMPLETED","sponsor":"Jonathan Roberts","startDate":"2015-07","conditions":"Von Willebrands Disease","enrollment":134},{"nctId":"NCT02792205","phase":"","title":"Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2017-02-22","conditions":"Von Willebrand Disease","enrollment":70},{"nctId":"NCT01334801","phase":"","title":"Biomarkers in Aortic Stenosis - B.A.S.S.","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-07","conditions":"Aortic Stenosis, Disorder of Prosthetic Cardiac Valve, Aortic Valve Insufficiency","enrollment":378},{"nctId":"NCT03205163","phase":"PHASE1, PHASE2","title":"A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2017-08-28","conditions":"Hemophilia A","enrollment":16},{"nctId":"NCT02933411","phase":"","title":"Low VW Activity in Adolescent HMB","status":"UNKNOWN","sponsor":"Baylor College of Medicine","startDate":"2017-01-05","conditions":"Von Willebrand Factor Deficiency","enrollment":120},{"nctId":"NCT05116501","phase":"NA","title":"Genetic Background of Patients With Low Von Willebrand Factor Levels","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2022-03-01","conditions":"Low Von Willebrand Factor","enrollment":300},{"nctId":"NCT05214300","phase":"","title":"Screening for Bleeding Disorders in Children","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2019-12-01","conditions":"Bleeding Disorder","enrollment":96},{"nctId":"NCT03095287","phase":"PHASE2","title":"Alphanate in Immune Tolerance Induction Therapy","status":"TERMINATED","sponsor":"Grifols Therapeutics LLC","startDate":"2018-01-03","conditions":"Hemophilia A, Congenital","enrollment":2},{"nctId":"NCT01051076","phase":"NA","title":"Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2009-11-03","conditions":"Severe Hemophilia A","enrollment":3},{"nctId":"NCT05008458","phase":"","title":"Value of Von Willebrand Factor and Copeptin Assay in Children With Febrile Seizures at Sohag University Hospital","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2021-09-01","conditions":"Febrile Seizure","enrollment":90},{"nctId":"NCT02973087","phase":"PHASE3","title":"rVWF IN PROPHYLAXIS","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-11-16","conditions":"Von Willebrand Disease","enrollment":29},{"nctId":"NCT02283268","phase":"PHASE3","title":"Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-04-01","conditions":"Von Willebrand Disease","enrollment":24},{"nctId":"NCT01410227","phase":"PHASE3","title":"Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-11-01","conditions":"Von Willebrand Disease","enrollment":49},{"nctId":"NCT00816660","phase":"PHASE1","title":"Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2008-12-01","conditions":"Von Willebrand Disease","enrollment":32},{"nctId":"NCT03956836","phase":"","title":"Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and HIPEC Intraperitoneal Chemotherapy (HIPEC)","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2020-03-27","conditions":"Coagulation Disorder, Carcinomatosis","enrollment":46},{"nctId":"NCT02954575","phase":"PHASE3","title":"Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A","status":"COMPLETED","sponsor":"Octapharma","startDate":"2016-12","conditions":"Severe Hemophilia A","enrollment":57},{"nctId":"NCT03376516","phase":"PHASE3","title":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-11-22","conditions":"Severe Hemophilia A","enrollment":11},{"nctId":"NCT01051544","phase":"NA","title":"Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2009-09-25","conditions":"Severe Hemophilia A","enrollment":""},{"nctId":"NCT03521583","phase":"","title":"Von Willebrand Disease in the Netherlands","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2019-07-28","conditions":"Von Willebrand Disease","enrollment":1100},{"nctId":"NCT04454775","phase":"","title":"Raloxifene on Coagulation System in the Postmenopausal Women","status":"COMPLETED","sponsor":"Karadeniz Technical University","startDate":"2005-12-01","conditions":"Raloxifene, Postmenopausal Women","enrollment":80},{"nctId":"NCT03204539","phase":"PHASE4","title":"INdividualized ITI Based on Fviii(ATE) Protection by VWF","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2017-06-01","conditions":"Hemophilia A With Inhibitor, Hemophilia A","enrollment":1},{"nctId":"NCT04324255","phase":"","title":"Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-01-01","conditions":"Liver Transplant; Complications","enrollment":1199},{"nctId":"NCT04317469","phase":"","title":"Evaluation of Von Willebrand Factor as a Marker For Early Diagnosis of Acute Respiratory Distress Syndrome (A.R.D.S) in Comparison to Interleukin 6 [IL-6]","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2020-03-21","conditions":"ARDS, Human","enrollment":60},{"nctId":"NCT03613584","phase":"PHASE2","title":"Von Willebrand Factor Concentrate During ECMO Support","status":"UNKNOWN","sponsor":"Tirol Kiniken GmbH","startDate":"2018-04-16","conditions":"Acquired Von Willebrand Disease","enrollment":68},{"nctId":"NCT04267406","phase":"","title":"ADAMTS-13 and Von Willebrand Factor Levels and Activities in Children With Cirrhosis and/or Portal Hypertension","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2019-01-02","conditions":"Coagulation Disorder, Cirrhosis, Liver","enrollment":64},{"nctId":"NCT02652975","phase":"NA","title":"Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-09","conditions":"Breast Neoplasms, Endothelial Dysfunction, Cardiovascular Disease","enrollment":76},{"nctId":"NCT02488525","phase":"PHASE3","title":"Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2016-01-20","conditions":"Heart Failure","enrollment":31},{"nctId":"NCT00524225","phase":"PHASE2","title":"IL-11 in Adults With Von Willebrand Disease Undergoing Surgery","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2008-02","conditions":"Von Willebrand Disease","enrollment":3},{"nctId":"NCT01949220","phase":"","title":"Willebrand International Non-interventional Global Surveillance","status":"COMPLETED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2014-03","conditions":"Von Willebrand Disease","enrollment":80},{"nctId":"NCT02506023","phase":"PHASE1","title":"Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-07","conditions":"Hemophilia A","enrollment":2},{"nctId":"NCT02552576","phase":"PHASE4","title":"Study of Voncento® in Subjects With Von Willebrand Disease","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2015-10-05","conditions":"Von Willebrand Disease","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19475,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Plasma-derived and/or recombinantVon Willebrand Factor (VWF) concentrates"],"phase":"marketed","status":"active","brandName":"von Willebrand factor","genericName":"von Willebrand factor","companyName":"National Center for Research Resources (NCRR)","companyId":"national-center-for-research-resources-ncrr","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Von Willebrand factor (vWF) is a blood glycoprotein that mediates platelet adhesion to damaged blood vessel walls and serves as a carrier protein for clotting factor VIII. Used for Von Willebrand disease (Types 1, 2, and 3), Hemophilia A (as factor VIII carrier).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}